Shots:
The US FDA has cleared the IND application of ES014 (anti-CD39xTGF-β bispecific Ab) to initiate a P-I clinical study for the treatment of advanced solid tumors
In preclinical studies, ES014 showed significant anti-tumor activity in a PD-1 resistant in vivo efficacy model
ES014 was designed to target CD39-adenosine & TGF-β pathways while anti-CD39 activity can reverse TME immunosuppression by reducing suppressive adenosine & maintains high levels of immune-stimulatory extracellular ATP. The company has built a robust pipeline of cancer immunotherapies covering oncology targets & multiple technologies including the BiME Ab platform for solid tumors
Ref: Businesswire | Image: Elpiscience
